Developing a Pulmonary Insulin Delivery System for Patients with Diabetes

Clinical Therapeutics

Volumn 29, Issue 6 PART 1, 2007, Pages 1271-1283

  Dailey, George ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HAGEDORN; HUMAN INSULIN; INSULIN; INSULIN ANTIBODY; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; ROSIGLITAZONE; SALBUTAMOL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DRUG TOLERABILITY; DRY POWDER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG FUNCTION; MEDICAL LITERATURE; MEDLINE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PUBLICATION; SIDE EFFECT; BLOOD; DRUG DELIVERY SYSTEM; INSTRUMENTATION; LUNG; META ANALYSIS; METABOLISM; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LUNG; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 38449084613     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.06.003     Document Type: Article

References (57)

1. Resnick H., Foster G., Bardsley J., and Ratner R. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002: The National Health and Nutrition Examination Survey. Diabetes Care 29 (2006) 531-537
2. Saydah S., Fradkin J., and Cowie C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
3. American Association of Clinical Endocrinologists. State of diabetes in America. Available at:. http://www.aace.com/newsroom/press/2005/FINALDataReport.pdf December 21, 2006
4. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28 (1995) 103-117
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). [published correction appears in Lancet. 1999;354:602]. Lancet 352 (1998) 837-853
7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). [published correction appears in Lancet. 1998;352:1558]. Lancet 352 (1998) 854-865
8. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 26 Suppl 3 (2002) S18-S24
9. Hunt L.M., Valenzuela M.A., and Pugh J.A. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 20 (1997) 292-298
10. Zambanini A., Newson R., Maisey M., and Feher M. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 46 (1999) 239-246
11. Dailey G. A timely transition to insulin: Identifying type 2 diabetes patients failing oral therapy. Formulary 40 (2005) 114-130
12. Miller L.S., Phillips C.D., Ziemer D.C., et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 161 (2001) 1653-1659
13. Jacobson A. Impact of improved glycemic control on quality of life in patients with diabetes. Endocr Pract 10 (2004) 502-508
14. Wilson M., Moore M., and Lunt H. Treatment satisfaction after commencement of insulin in type 2 diabetes. Diabetes Res Clin Pract: 66 (2004) 263-267
15. Vinik A., and Zhang Q. Adding insulin glargine versus rosiglitazone: Health-related quality-of-life impact in type 2 diabetes. Diabetes Care 30 (2007) 795-800
16. Juliusson P., Graue M., Wentzel-Larsen T., and Sovik O. The impact of continuous subcutaneous insulin infusion on health-related quality of life in children and adolescents with type 1 diabetes. Acta Paediatr 95 (2006) 1481-1487
17. Owens D., Zinman B., and Bolli G. Alternative routes of insulin delivery. Diabet Med 20 (2003) 886-898
18. Patton J. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 19 (1996) 3-36
19. Barnett A.H. Exubera inhaled insulin: A review. IntJ Clin Pract 58 (2004) 394-401
20. Patton J. Deep-lung delivery of therapeutic proteins. Chemtech 27 (1997) 34-38
21. Exubera inhalation powder (2006), Pfizer Inc, NewYork, NY [package insert]
22. Rave K., Bott S., Heinemann L., et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 28 (2005) 1077-1082
23. Gelfand R.A., Schwartz S.L., Horton M., et al. Pharmacological reproducibility of inhaled human insulin dosed pre-meal in patients with type 2 diabetes mellitus. Diabetes 51 (2002) A202 Abstract 773
24. Mudaliar S., Henry R.R., Fryburg D.A., et al. Within-subject variability of inhaled insulin (Exubera) versus subcutaneous regular insulin in elderly obese patients with type 2 diabetes mellitus. Diabetologia 46 SuppI 2 (2003) A277 Abstract 802
25. Fountaine R.J., Milton A., Wei G., et al. Effects ofalbuterol and fluticasone on inhaled human insulin (Exubera) pharmacokinetics in patients with mild-to-moderate asthma. Diabetes 55 Suppl 1 (2006) A112 Abstract 469-P
26. Quattrin T., Belanger A., Bohannon N.J., Schwartz S.L., and Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 27 (2004) 2622-2627
27. Skyler J.S., Weinstock R.S., Raskin P., et al., Inhaled Insulin Phase II Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: A 6-month, randomized, comparative trial. Diabetes Care 28 (2005) 1630-1635
28. Cefalu W.T., Skyler J.S., Kourides I.A., et al., Inhaled Insulin Study Group. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 134 (2001) 203-207
29. Hollander P., Blonde L., Rowe R., et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 27 (2004) 2356-2362
30. Weiss S.R., Cheng S.L., Kourides I.A., et al., Inhaled Insulin Phase II Study Group. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: A randomized controlled trial. Arch Intem Med 163 (2003) 2277-2282
31. DeFronzo R.A., Bergenstal R.M., Cefalu W.T., et al., Exubera Phase III Study Group. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: A 12-week, randomized, comparative trial. Diabetes Care 28 (2005) 1922-1928
32. Rosenstock J., Zinman B., Murphy L., et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: A randomized, controlled trial. Ann Intern Med 143 (2005) 549-558
33. Barnett A.H., Dreyer M., Lange P., and Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 29 (2006) 1282-1287
34. Barnett A., Dreyer M., Lange P., and Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care 29 (2006) 1818-1825
35. Rosenstock J., Cappelleri J., Bolinder B., and Gerber I. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera)in patients with type 1 or type 2 diabetes. Diabetes Care 27 (2004) 1318-1323
36. Testa M.A., Turner R.R., Hayes J.F., et al. Satisfaction and quality of life with sulfonylurea plus either metformin or Exubera: An international randomized phase 3 trial. Diabetes (2004) 53 Abstract 487-P
37. Freemantle N., Blonde L., Duhot D., et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 28 (2005) 427-428
38. Fineberg S.E., Kawabata T., Finco-Kent D., et al. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 90 (2005) 3287-3294
39. Heise T., Bott S., Tusek C., et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: A prospective randomized pharmacodynamic study. Diabetes Care 28 (2005) 2161-2169
40. Rosenstock J., Foyt H., Klioze S., et al. Inhaled human insulin (Exubera) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 2 diabetes (T2DM). Diabetes 55 Suppl 1 (2006) A26 Abstract 109-OR
41. Skyler J.S., Jovanovic L., Klioze S., et al., Inhaled Human Insulin Type 1 Diabetes Study Group. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 30 (2007) 579-585
42. Skyler J., and Exubera Phase 2 Study Group. Sustained long-term efficacy and safety of inhaled insulin during 4 years of continuous therapy. Diabetes 53 Suppl 2 (2004) A115 Abstract 486-P
43. French J.L., Tensfeldt T.G., Riese R.J., Teeter J.G., and Exubera Phase 3 Development Team. Disease progression modeling to characterize the effects of inhaled insulin (Exubera) on FEV1. Presented at: Annual International Conference of the American Thoracic Society; May 19-24 (2006) San Diego, Calif
44. Jones J., Minty B., Lawler P., et al. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1 (1980) 66-68
45. Witten M., Lemen R., Quan S., et al. Acute cigarette smoke exposure increases alveolar permeability in rabbits. Am Rev Respir Dis 132 (1985) 321-325
46. Sha S., Becket R.H., Willavise S.A., et al. The effect of smoking cessation on the absorption of inhaled insulin (Exubera). Diabetes 51 Suppl 2 (2002) A133 Abstract 538-P
47. Ceglia L., Lau J., and Pittas A. Meta-analysis: Efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 145 (2006) 665-675
48. Patton J., Bukar J., and Eldon M. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 43 (2004) 781-801
49. Laube B.L. Treating diabetes with aerosolized insulin. Chest 120 Suppl 3 (2001) 99S-106S
50. Mathieu C. Inhaled human insulin ([insulin human (rDNA origin)] inhalation powder) in diabetes mellitus. Expert Opin Drug Metab Toxicol 2 (2006) 779-791
51. Brain J.D. Unlocking the opportunity of tight glycaemic control. Inhaled insulin: Safety. Diabetes Obes Metab 7 Suppl 1 (2005) S14-S18
52. Hsia C., and Raskin P. The diabetic lung: Relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med 118 (2005) 205-211
53. de Galan B., Simsek S., Tack C., and Heine R. Efficacy and safety of inhaled insulin in the treatment of diabetes mellitus. Neth Med 64 (2006) 319-325
54. Patton J.S., and Platz R.M. Aerosol insulin3-A brief review. In: Byron P.R., Dalby R.N., and Farr S.J. (Eds). Respiratory Drug Delivery IV (1994), Interpharm Press, Buffalo Grove, III 65-74
55. Peyrot M., Rubin R.E., Lauritzen T., et al., International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28 (2005) 2673-2679
56. Odegard P., and Capoccia K. Inhaled insulin: Exubera. Ann Pkarmacotker 39 (2005) 843-853
57. Scherbaum W.A. Unlocking the opportunity of tight glycaemic control. Inhaled insulin: Clinical efficacy. Diabetes Obes Metab 7 Suppl 1 (2006) S9-S13